Trial · NCT04605393
Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Study
NCT04605393, Not applicable, Completed, King's College London
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Study. Trials, record NCT04605393. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04605393
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Study
- NCT number
- NCT04605393
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 36 participants, actual
- Lead sponsor
- King's College London
- Conditions
- Schizophrenia, Cannabis Use
- Interventions
- Cannabidiol, Placebo, Delta-9-THC
- First posted
- 2020-10-28
- Last updated
- 2023-08-18
Source ClinicalTrials.gov
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hopkins Verbal Learning Test | Baseline visit; 20 mins post-THC | Delayed verbal recall |
| Primary | Positive and Negative Syndrome Scale | pre-CBD/placebo administration, and from immediately after THC inhalation until the end of study visit (i.e. 2-3 hours post-THC) | Positive Subscale |
| Secondary | State-Trait Anxiety Inventory | pre-CBD/placebo administration, pre-THC and 20mins post-THC | State Scale |
| Secondary | Digit span | Baseline; 25 mins post-THC | Forward \& Reverse |
| Secondary | Hopkins Verbal Learning Test | Baseline; 20 mins post-THC | Immediate verbal recall |
| Secondary | Positive and Negative Syndrome Scale | pre-CBD/placebo administration, and from immediately after THC inhalation until the end of study visit (i.e. 2-3 hours post-THC) | Negative Subscale |
| Secondary | Visual analogue scales | pre-CBD/placebo, 90mins post CBD, pre-THC, and +10mins, +45mins, +90mins post-THC inhalation, and at the end of study visit (i.e. 2-3 hours post-THC) | * Feel drug effect * Like drug effect * Want more drug * Thinking clearly * Tired * Excited * Want to talk * Anxious * Relaxed * Happy * Irritable * Suspicious * Hearing voices * Dry mouth * Hungry |
| Secondary | Psychotomimetic states inventory | pre-CBD/placebo administration, and at the end of study visit (i.e. 2-3 hours post-THC) | |
| Secondary | State Social Paranoia Scale | pre-CBD/placebo administration, and at the end of study visit (i.e. 2-3 hours post-THC) | |
| Secondary | Study drug preference | End of Experiment 2 | At the end of the final experimental visit (i.e. 2-3 hours post-THC), participants will be asked to order the two experimental visits according to which drug combination they found most pleasurable. |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 40702165 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Verbal Learning | Primary outcome | ConductCognition |
| Advice Taking Task | Secondary outcome | ConductCognition |
| Digit Span Test | Secondary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04605393
GET https://conductscience.org/api/trials/v1/NCT04605393/registered